A decreasing trend in active TGFβ levels was also observed in paired biopsy specimens in Part 2 expansion studies at 7.5 or 22.5 mg/kg DLs (Figure 2 ).
← all excerpts
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
1
—
—